Fundsmith LLP Has $917.39 Million Holdings in Stryker Corporation $SYK

Fundsmith LLP lessened its position in shares of Stryker Corporation (NYSE:SYK) by 4.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,913,833 shares of the medical technology company’s stock after selling 147,583 shares during the quarter. Stryker accounts for 6.7% of Fundsmith LLP’s portfolio, making the stock its 2nd biggest holding. Fundsmith LLP owned 0.76% of Stryker worth $917,391,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Gables Capital Management Inc. purchased a new position in shares of Stryker in the second quarter worth approximately $25,000. Kilter Group LLC purchased a new position in shares of Stryker during the 2nd quarter valued at about $25,000. Godfrey Financial Associates Inc. bought a new position in shares of Stryker during the 4th quarter valued at approximately $26,000. Sankala Group LLC purchased a new stake in Stryker in the 4th quarter worth approximately $26,000. Finally, Compass Financial Management LLC bought a new stake in Stryker during the 2nd quarter worth approximately $27,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Up 0.2%

SYK opened at $331.32 on Monday. The company has a market capitalization of $127.08 billion, a PE ratio of 34.33, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The firm has a 50-day simple moving average of $329.10 and a two-hundred day simple moving average of $331.29. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is 36.48%.

Insider Activity

In other news, insider Debra King sold 826 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares in the company, valued at $773,031,862.50. This represents a 11.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on SYK shares. Piper Sandler dropped their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Argus set a $370.00 price objective on shares of Stryker in a research report on Thursday, July 9th. Leerink Partners lowered their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. JPMorgan Chase & Co. dropped their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Finally, Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.